Relmada Therapeutics, Inc.

About Relmada

Addressing areas of high unmet needs in the treatment of central nervous system (CNS) disorders.

Overview

We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders.

REL-1017 Development Pipeline

Indication 2018 2019
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Major Depressive Disorder Rel-1017 Ph2aCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarter
Rett Syndrome PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Ophthalmology Formulation & PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Mitochondrial Diseases / ALS PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
*Depends on preclinical results, FDA feedback and available capital resources.
Clinical
Preclinical

Corporate Strategy

We leverage our considerable industry and development experience, and disease knowledge to identify, develop and commercialize product candidates for CNS conditions with high unmet needs. Our strategy focuses on developing REL-1017 (dextromethadone) in depression, Rett syndrome, and other ophthalmology and CNS diseases where REL-1017 mechanism of action could have a major therapeutic impact.

We will continue to prioritize our product development activities, including existing drug assets, REL-1015, REL-1028, and REL-1021, after taking into account the resources we have available, market dynamics and potential for value addition. We will continue to outsource development of our products, while retaining scientific, operational and financial oversight and control.

Leadership

Charles J. Casamento, MBA

Chairman of the Board

Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  He was president and CEO of Osteologix from October 2004 until April 2007. Mr. Casamento was the founder of Questcor…

Paul Kelly, MBA

Director

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS…

Maged Shenouda, R.Ph, MBA

Director

Mr. Shenouda has over 25 years of biotechnology and equity research experience. He is currently Chief Financial Officer of AzurRx BioPharma. He was previously head of business development and licensing at Retrophin, Inc. from January 2014…

Sergio Traversa, PharmD, MBA

Chief Executive Officer and Interim Chief Financial Officer

Before joining Relmada, Dr. Traversa was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United States…

Dr. Ottavio Vitolo, MD

Senior Vice President, Head of R&D and Chief Medical Officer

Dr. Vitolo is a neuropsychiatrist and researcher with extensive pre-clinical and clinical research experience in both academic and industry settings. Previously he held positions of increasing responsibility at Pfizer, including senior…

Maurizio Fava

Dr. Maurizio Fava is director, Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, executive vice chair of the Department of Psychiatry and executive director of the Clinical Trials Network and Institute, (MGH), and associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Charles Inturrisi

Charles E. Inturrisi, PhD, is professor of pharmacology, Weill Medical College of Cornell University; professor, Programs in Pharmacology and Neuroscience, Weill Graduate School of Medical Sciences of Cornell University; and visiting investigator, Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center.

Paolo Manfredi

Dr. Paolo Manfredi is board certified in Neurology and Psychiatry, in Pain Medicine and in Hospice and Palliative Care. He has completed fellowships at MD Anderson Cancer Center and Massachusetts General Hospital, where he obtained the Golden Needle Award. He has served as the Director of Pain Management and Palliative Care Program at Mount Sinai Medical Center where he was Assistant Professor in Neurology, Anesthesia and Geriatric Medicine.

Michael E. Thase, MD

Dr. Michael E. Thase joined the faculty of the Perelman School of Medicine at the University of Pennsylvania in 2007 as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic.